Clinical trials: Smokers
Smoking Cessation
Assessing Neuropsychiatric Symptoms Including Depression, Anxiety, Irritability, and Suicidal Thoughts or Behavior in Subjects Quitting Smoking on Varenicline Tartrate or Placebo
Study objective is to compare neuropsychiatric adverse events in subjects treated with varenicline or placebo in a controlled setting where both groups are experiencing nicotine withdrawal.
- Trial name
- NCT00749944
- Testing
- varenicline
- Where
- 2 sites in United States
- Volunteers
- 110 people
- Sponsor
- Pfizer
Smoking Cessation
A Study Evaluating the Absorption Of Varenicline Through The Skin Following Once Daily Application Of A Patch For 14 Days
This study will evaluate the steady-state pharmacokinetics, safety and tolerability of a varenicline patch applied once daily to the skin for 14 days.
- Trial name
- NCT01234142
- Testing
- varenicline free base patch
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Pfizer
COPD
The Effect of Inhaled PUL-042 on Rhinovirus-induced Symptoms in Smokers With GOLD Stage 0 COPD
This is a study examining the effect of inhaled PUL-042 on peak lower respiratory symptoms as measured by subject diary in early stage COPD subjects who are experimentally infected with rhinovirus.
- Trial name
- NCT03794557
- Testing
- Sterile Water Injection, PUL-042 Inhalation Solution
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Pulmotect, Inc.
Chronic Smokers, Hyperlipidemia
Efficacy and Safety Study of Dietary Supplements in Chronic Smokers Having Mild to Moderate Hyperlipidemia
The purpose of this study is to investigate the efficacy and safety of dietary supplements (BioTurmin, BioTurmin-WD and MaQxan) on cotinine level and oxidative stress marker in chronic smokers having mild to moderate…
- Trial name
- NCT02203227
- Testing
- BioTurmin (Curcuma longa rhizomes extract), BioTurmin-WD (Water dispersible curcuminoids), MaQxan
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Olive Lifesciences Pvt Ltd
Tobacco Use, Smoking
CSD231005 Nicotine Pouch Biomarkers of Exposure
This will be a multi center open label, randomized, controlled, switching parallel-group study designed to assess changes in select biomarkers of exposure (BoE) in generally healthy smokers following a 5 day in-clinic switch to…
- Trial name
- NCT06303115
- Testing
- Nicotine Pouch P1312914, 4 mg nicotine, Nicotine Pouch P1312915, 8 mg nicotine, Nicotine Pouch P1013215, 8 mg nicotine
- Where
- 5 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- RAI Services Company
Healthy Volunteers
A Study to Evaluate Nicotine Uptake and Biomarkers in Adult Smokers Using mybluTM Electronic Cigarettes
This study evaluates the overall performance of the currently-marketed MybluTM e-cigarette device and pods, as assessed by nicotine uptake, exposure to smoke constituents, safety and consumer satisfaction, over 8 days.
- Trial name
- NCT04429932
- Testing
- Myblu flavor A_2.4, Myblu flavor B_2.4, Myblu flavor C_2.4
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Fontem US LLC
Lung Cancer
Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphyrin (TCPP) for Detection of Lung Cancer
The primary objective of this study is optimization of the assay to discriminate between cancer cells and non-cancer cells in sputum samples by the performance of experiments that will determine methods to liquefy sputum, select…
- Trial name
- NCT03837600
- Where
- 5 sites in United States
- Volunteers
- 197 people, healthy volunteers welcome
- Sponsor
- bioAffinity Technologies Inc.
Healthy
A Study to Assess the Nicotine Pharmacokinetics, Tolerability and Safety With a New Oral Nicotine Replacement Product in Healthy Japanese Smokers
In Part 1, the purpose of this study is to elucidate the single-dose pharmacokinetic profiles of 1 spray and 2 consecutive sprays of oromucosal nicotine spray (ONS) in comparison with those of nicotine gum and cigarette smoking…
- Trial name
- NCT03398876
- Testing
- Oromucosal Nicotine Spray (ONS), Nicotine Gum, Cigarette
- Where
- Japan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Janssen Pharmaceutical K.K.
Tobacco Use Disorder
A Bioequivalence Study of Three, 2 mg Nicotine Chewing Gums (Two Tests and One Reference) in Healthy Adult Smokers
This is a randomized, open-label, single-dose, three-period, crossover, single-center comparative bioavailability (BA) study under fasting condition in Chinese healthy male adult participants with a history of cigarette smoking.
- Trial name
- NCT02688374
- Testing
- Treatment A: Nicorette 2 mg coated mint gum, Treatment B: Nicotinell 2 mg coated mint gum, Treatment C: Nicotinell 2 mg coated fruit flavor gum
- Where
- China
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Smoking Cessation
Comparison of Pharmacokinetic Profiles of 3 New Nicotine Gum Formulations With a Reference Gum
The purpose of the study is to compare the pharmacokinetic (PK) profiles and assess bioequivalence between three new nicotine gum formulations and a reference nicotine gum in healthy smokers.
- Trial name
- NCT02356913
- Testing
- Nicotine gum
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Fertin Pharma A/S
Smoking Cessation
A Multi-National Study To Assess How Effective And Safe The Smoking Cessation Medicine Varenicline Is In Smokers Who Have Already Tried Varenicline In The Past As A Prescription Medicine From Their Usual Healthcare Provider
The main purpose of this study is to compare the effectiveness and safety of the re-treatment of smokers with varenicline with placebo for smoking cessation during the last 4 weeks of a 12 week course of treatment.
- Trial name
- NCT01244061
- Testing
- Varenicline
- Where
- 37 sites in United States, Australia and 6 more
- Volunteers
- 498 people
- Sponsor
- Pfizer
Smoking
CSD170501: Study to Assess Biomarkers of Tobacco Exposure in Smokers During In-Clinic Confinement Switch to an Electronic Cigarette
The purpose of this clinical study is to evaluate changes in biomarkers of exposure (BOE) to tobacco smoke constituents after smokers switch from combustible cigarettes to use of one of the three electronic cigarettes or…
- Trial name
- NCT03170674
- Testing
- FT21039, FT21092, FT21018
- Where
- 2 sites in United States
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- RAI Services Company
Non Small Cell Lung Cancer
A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer
The purpose of this study is to compare two different approaches to treating non-small cell lung cancer (NSCLC) in East Asian never-smoker participants.
- Trial name
- NCT01017874
- Testing
- Pemetrexed, Cisplatin, Gefitinib
- Where
- 12 sites in Hong Kong, Singapore and 3 more
- Volunteers
- 236 people
- Sponsor
- Eli Lilly and Company
Tobacco Use
Pharmacokinetic and Subjective Effects of Heated Tobacco Products
This is a randomized, controlled, six-way crossover clinical study to characterize the nicotine PK (pharmacokinetic) and subjective effects of HTPs (Heated Tobacco Products) comprised of 2 menthol varieties and 2 tobacco flavor…
- Trial name
- NCT06356610
- Testing
- Product A, Product B, Product C
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- Altria Client Services LLC
Substance Dependence
A Human Volunteer Study Investigating Single Oral Doses of GSK598809 in Otherwise Healthy Smokers
Study to investigate the safety, tolerability and pharmacokinetics of GSK598809 in otherwise healthy volunteers. This study is required because this drug is being developed for the treatment of nicotine dependence.
- Trial name
- NCT00728052
- Testing
- GSK598809
- Where
- Germany
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 2
A Clinical Trial to Assess the Safety of Oral SRT2104 and Its Effects on Vascular Dysfunction in Otherwise Healthy Cigarette Smokers and Subjects With Type 2 Diabetes Mellitus
The primary purpose of this study is to evaluate the safety and tolerability of SRT2104 (2.0 g administered once daily for 28 days) and to examine the effects of SRT2104 (2.0 g administered once daily for 28 days) on reversing…
- Trial name
- NCT01031108
- Testing
- SRT2104
- Where
- United Kingdom
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Sirtris, a GSK Company
Smoking Behaviors, Smoking ( Cigarette)
A Study to Assess Nicotine Uptake From a Menthol Electronic Nicotine Delivery System Product
This will be a randomized, open-label, 2-way crossover, single-site study designed to evaluate elements of abuse liability (AL), including subjective effects and physiological measures (pharmacodynamics [PD]), and plasma nicotine…
- Conditions
- Smoking Behaviors, Smoking ( Cigarette), Tobacco Use, Abuse Liability
- Trial name
- NCT07881848
- Testing
- Menthol 5%, Combustible cigarette
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- RAI Services Company
Healthy
Clinical Trial to Assess Pharmacodynamic Effects on Segmental Endotoxin Induced Inflammatory Response of BI 1026706 Versus Placebo
The primary and secondary objectives of the current study are the assessments of anti-inflammatory pharmacodynamic effects on segmental endotoxin induced inflammatory response after 4 weeks treatment with BI 1026706.
- Trial name
- NCT02657408
- Testing
- BI 1026706
- Where
- Germany
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Tobacco Use
Study to Evaluate Changes in Smokers Using on!® Nicotine Pouches
The purpose of this study is to generate evidence regarding the extent of reduction in exposure to selected HPHCs in adult smokers switching to on!® NPs.
- Trial name
- NCT05664672
- Testing
- OTDN Product 1, OTDN Product 2, OTDN Product 3
- Where
- 3 sites in United States
- Volunteers
- 149 people, healthy volunteers welcome
- Sponsor
- Altria Client Services LLC
Schizophrenia
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
This is an efficacy study evaluating a experimental treatment for cognitive deficits in adults with schizophrenia.
- Trial name
- NCT01678755
- Testing
- ABT-126
- Where
- 20 sites in United States
- Volunteers
- 157 people
- Sponsor
- AbbVie (prior sponsor, Abbott)